Amnavero.
← Research directory

Research profile

Bremelanotide/PT-141

Bremelanotide, also called PT-141, activates melanocortin receptors. An approved U.S. prescription formulation is indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

  • Phase 3 clinical trials
  • Evaluation only
Amnavero Bremelanotide/PT-141 research vial concept packaging
Amnavero Bremelanotide/PT-141
Concept packaging

What the research found

Two phase 3 trials evaluated patient-reported sexual desire and distress. Both measures improved with bremelanotide relative to placebo.

What remains uncertain

The evidence covers the population studied. The prescribing information includes cardiovascular restrictions and describes common adverse reactions such as nausea.